Invest in AMILI | The Future of Microbiome-Based Health Solutions

Invest in the Future of Gut Healthwith AMILI

At AMILI, we are pioneering the future of gut health with precision microbiome solutions tailored to the Asian population. As a forward-thinking company committed to scientific innovation, we offer unique opportunities for investors to join us on our journey to transform healthcare in Asia and beyond.

AMILI is a gut health data insight and analytics platform. By operating end-to-end, AMILI captures richer, more accurate insights into gut microbiome abundance, functionality and health impact.

Our Investors

At AMILI, we are backed by world-class investors who share our passion for revolutionising gut health. Their support fuels our groundbreaking work in microbiome science and propels us toward a healthier future.

$20 MILLION RAISED FOR SERIES A

AMILI and Partners have raised 20 Million SGD, with investors from biotech, healthcare and foodtech industries

$60+ MILLION IN RESEARCH GRANTS

Awarded to AMILI and Partners
 These grants have enabled more than 20 research studies, exploring bold hypotheses in microbiome science and advancing innovation in healthcare and nutrition.

Why AMILI?

AMILI stands out in the competitive landscape of gut health due to several key factors that investors look for in high-potential businesses

Asia’s First Precision Microbiome Company

Redefining gut health with innovative solutions.

Asia’s Largest Microbiome Database

A treasure trove of insights for science and application.

A Legacy of Impact

From research breakthroughs to actionable, data-driven solutions, AMILI is at the forefront of microbiome innovation.

Microbiome Global Market

CAGR

17.1%

Projected to grow from US$717.2M in 2024 to US$2.97B by 2033

CAGR

17.5%

Diagnostics sector expected to reach US$416M by 2030

Home Gut Microbiome Testing Market

Functional Foods and Beverages Market

CAGR

15%

Estimated at US$0.5B in 2022, forecast to hit US$1.5B by 2030

83%

Probiotics dominate with 83% revenue share in 2023, driven by consumer focus on gut health

AMILI Analytics

AMILI Analytics provides FMCG partners with the insights and tools to create microbiome-enabled personalised products and services. Our services rely heavily on AMILI's multi-ethnic Asian database and Food-microbe database

AMILI Analytics offers 3 products:

In-vitro testing: Validating the microbial impact from specific products (e.g., food ingredients)
Human studies: In-depth study of physiological and gut changes from product consumption
Data science research: Microbiome analytics leveraging AMILI’s proprietary Metagenome-Assembled Genome (MAG) library and analytics pipeline

Learn More

AMILI Health

AMILI Health is AMILI’s clinic engagement arm, partnering with healthcare professionals to provide high quality products that support improved gut microbiome health for patients

AMILI Health offers 3 products:

Microbiome Transplant service: Transplants for appropriate dysbiotic patients
Gut Health Test: Gut microbiome sequencing with insights report
Probiotics: 4 formulations that are tailored to the Asia microbiome

Learn More

AMILI Biosciences

AMILI Biosciences is AMILI’s research and development arm, developing FDA and HAS-approved microbiome diagnostics and therapeutics to transform health.

Learn More

AMILI's Unique Market Position

We are Southeast Asia’s first and only precision gut microbiome company, with the biggest proprietary multiethnic Asian database in the world. Our cutting-edge solutions, including gut health testing, probiotics, and faecal microbiota transplants (FMT), are designed to address the unique needs of the Asian population—a market often overlooked by Western-centric research. We have established strong ties with leading institutions like NUS, NTU, and Monash University and are backed by reputable funders such as Cercano, Pruska and many more.

Strong Growth Potential

With the global microbiome market expected to continue its rapid growth, AMILI is poised to capture significant market share in Asia. We are committed to scaling our solutions, expanding into new markets, and continuing our research and development efforts to advance precision medicine. Our growth strategy includes enhancing our product offerings, forming strategic partnerships, and capitalising on the increasing awareness of gut health’s role in overall well-being.

Innovative and Scalable Products

Our solutions are scientifically validated and cater to a diverse range of patient needs, from digestive health to mental well-being. With products like the Gut Health Test (GHT), personalised probiotics, and our FMT services, we offer scalable solutions that can be integrated into healthcare practices across the region. Our approach is data-driven and technology-backed, ensuring sustainable, long-term growth.

A Competent and Experienced Team

Our leadership team brings together expertise in microbiome science, healthcare, technology, and business strategy. The team’s deep knowledge and commitment to advancing gut health ensure that AMILI remains at the cutting edge of innovation. We’re continuously expanding our team to meet the growing demands of the market and are always looking for professionals who share our vision and drive.

Dr. Jeremy Lim

Chief Executive Officer

Dr. Chris Ting

Co-Founder

Dr. David Ong

Chief Medical Officer and Co-Founder

Dr. Jonathan Lee

Scientific Co-Founder

Manu Swarup

Chief Operation Officer

Jit Han Tan

Chief Growth Officer

Dr. Pijika Watcharapichat

Head of Medical and Clinical Informatics

We invite you to explore the exciting opportunities to invest in AMILI.
‍
If you’re interested in joining us in shaping the future of gut health, we’d love to connect with you.

Let's get started with us.

For more information on investment opportunities with AMILI.